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SocietyLeptin is a 16 kDa non-glycosylated peptide hormone
encoded by the gene obese (ob), the murine homologue
of the human gene LEP1. Structurally, it belongs to the class
I cytokine superfamily, consisting of a bundle of four a-heli-
ces. It is mainly produced by adipocytes, and circulating
leptin levels are directly correlated with white adipose tissue
mass. It decreases food intake and increases energy con-
sumption by acting on hypothalamic cell populations. Its
own synthesis is mainly regulated by food intake and eat-
ing-related hormones, but also depends on energy status,
and a wide range of inﬂammation mediators2. As a result
of the effects of sex hormones, leptin levels are higher in
women than in men even when adjusted for body mass in-
dex, which may be relevant to the inﬂuence of sex on the
development or frequency of certain diseases3, such as
osteoarthritis (OA)4. It can be accordingly described as
a cytokine-like hormone with pleiotropic actions. For patho-
logical conditions to which dysregulated leptin activity con-
tributes (see below), the blockade/activation of this activity
in speciﬁc target tissues may be a useful therapeutic strat-
egy in the near future.
Leptin exerts its biological actions by binding to its recep-
tors. These are encoded by the gene diabetes (db) and be-
long to the class I cytokine receptor superfamily, which
includes receptors for interleukin 6 (IL6), Leukemia Inhibitory
Factor (LIF), Ciliary Neurotrophic Factor (CNTF), Oncostatin
M (OSM), Granulocyte colony stimulating factor (G-CSF) and
gp130. Alternative splicing of db gives rise to six receptor iso-
forms: the soluble form Ob-Re, which lacks a cytoplasmic
domain; four forms with short cytoplasmic domains (Ob-Ra,
Ob-Rc, Ob-Rd and Ob-Rf); and the long form Ob-Rb, which
is found in almost all tissues and appears to be the only
form capable of transducing the leptin signal.
As in the case of other class I cytokine receptors, the
main routes by which Ob-Rb appears to transmit the extra-
cellular signal it receives are Janus kinase(s) (JAK)-signal
transducers and activators of transcription (STAT) path-
ways5, which involve JAK2 phosphorylation of tyrosines in
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ternative pathways are at play6.
The early studies of leptin focused on its anorexigenic ac-
tion, although leptin therapy is not an effective treatment for
morbid obesity that is not due to congenital deﬁciency of
leptin or leptin receptors.
Leptin plays also a relevant role in immunity, and known
direct actions of leptin on immune responses include the fol-
lowing: promotion of phagocyte function and induction of
the synthesis of eicosanoids, nitric oxide and several pro-
inﬂammatory cytokines in macrophages and monocytes; in-
duction of chemotaxis and the release of reactive oxygen
species by neutrophils; and modulation of natural killer
(NK) and dendritic cell activity. However, a critical ﬁnding
of most of the studies focussed on the interaction between
leptin and the immune system was the demonstration that it
modiﬁes T-cell balance, induces T-cell activation, and alters
the pattern of T-cell cytokine production by directing T-cell
differentiation toward a TH1 response
7, accounting for
a pro-inﬂammatory role of leptin in several models of auto-
immune/inﬂammatory conditions.
Although it is mainly known for, and tightly associated with,
the control of appetite, leptin, as mentioned above, is more
than an antiobesity molecule. Indeed, leptin is also a major
regulator of bone mass, and the role of leptin in bone homeo-
stases was recently reviewed8. However, it was not until late
2001 that the ﬁrst report on the effect of leptin on chondro-
cytes was published by Figenschau et al.9 This paper led
to a renewed interest in the potential roles of leptin on this
particular cell type and other data soon came out.
Together with a number of other neuroendocrine mes-
sengers, leptin appears to play a major role in diseases af-
fecting articular cartilage such as rheumatoid arthritis and
OA. In patients with rheumatoid arthritis, circulating leptin
levels are high10,11, and leptin production is much higher
in OA cartilage than in normal cartilage12.
Of all the connective tissues that compose a skeletal
joint, articular cartilage is the most damaged by rheumatic
disease. Under pathological conditions, control of the bal-
ance between synthesis and degradation of extracellular
matrix by chondrocytes is lost, and the production of
a host of inﬂammation mediators by these cells eventually
leads to complete loss of cartilage structure13,14. The initial
ﬁnding that administration of exogenous leptin increases
insulin-like growth factor I (IGF1) and Transforming growth
factor-beta 1 (TGFb1) production by rat knee joint cartilage7
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dividuals may protect cartilage from degeneration in OA12.
However, most of the evidence points the other way: in
rheumatoid arthritis patients, a fasting-induced fall in
circulating leptin is associated with CD4þ lymphocyte
hyporeactivity and increased IL4 secretion15; experimental
antigen-induced arthritis is less severe in leptin-deﬁcient
ob/ob mice than in wild-type mice16; and in cultured chon-
drocytes type 2 nitric oxide synthase (NOS2) is activated
by the combination of leptin plus Interferon-gamma (IFNg)
(though not by either without the other)17, and NOS2 activa-
tion by IL1 is increased by leptin18. Nitric oxide has well-
documented pro-inﬂammatory effects on joint cartilage,
triggering the loss of chondrocyte phenotype, and inducing
chondrocyte apoptosis and the activation of metallopro-
teases. Intracellularly, the joint action of IL1 and leptin
involves JAK2, phosphatidylinositol-3 kinase (PI3K), MAPK/
ERK kinase 1 (MEK1) and p38.
A pro-inﬂammatory effect of leptin on cartilage would be in
keeping with the fact that, in comparison with men, women
have both higher circulating leptin levels and a greater pro-
pensity to develop OA4. It would also explain the association
between obesity and inﬂammatory conditions, especially
those related with alterations of cartilage homeostasis.
In the present issue of Osteoarthritis & Cartilage, the
group of Simopoulou and collaborators19 investigates the
role of leptin and leptin receptors in a very novel and intrigu-
ing manner by comparing both mRNA expression and pro-
tein in advanced and minimal OA affected cartilage but also
in normal cartilage. In addition, these authors determined
also the effect of leptin on cartilage metabolism in terms
of leptin receptor long form expression, IL1 and nitric oxide
but also evaluating the response to leptin of relevant metal-
loproteases involved in cartilage damage such as matrix
metalloproteinase 9 (MMP9) and MMP13 (Fig. 1).
All these data conﬁrm the hypothesis that OA is a
metabolic disease in which systemic and local factorssigniﬁcantly contribute to the prominent dysregulation pres-
ent in the disease. The ﬁrst relevant observation coming out
from this study is the differential expression of leptin and its
functional receptor in severely damaged cartilage and in
minimally affected cartilage being higher in the severely
damaged tissue. This type of experimental approach is truly
convincing and avoids external interferences of other vari-
ables such as age, genetic background, differences in the
pharmacological treatments as well as artifacts due to spec-
imen collection. Indeed, the comparisons are carried out be-
tween cartilage samples from the same individual. Although
the authors acknowledged that minimally affected OA carti-
lage cannot be considered as normal cartilage, one may as-
sume that mildly damaged OA cartilage adjacent to OA
lesions, represents a pre-challenged tissue which has all
the potential to perpetuate the degenerative process, and
can be considered easily as a mirror of what is happening
along the development of the disease.
Another relevant aspect arising from this study is the con-
ﬁrmation that obesity, a pathologic situation characterized
by a systemic hyperleptinaemia, leptin resistance, and
a ‘‘low grade inﬂammatory state’’ contributes signiﬁcantly
to a dramatic increase of leptin expression in cartilage of
obese individuals. This aspect suggests that in obese sub-
jects, hyperleptinaemia may be also present at local level
and may account for diverse effects such as the downregu-
lation of leptin functional receptor expression or the inhibi-
tion of the downstream signaling pathways through the
induction of regulator molecules such as Suppressor of cy-
tokine signaling 3 (SOCS3). The authors in this article ad-
dressed a decrease of expression of the functional leptin
receptor in normal chondrocytes challenged with leptin,
whereas OA chondrocytes are likely to be refractory to
this kind of regulation. So, in these terms a local leptin re-
sistance is unlikely. On the contrary, the increased expres-
sion of leptin in markedly damaged cartilage, together with
elevated leptin levels in synovial ﬂuid (which could be alsoFig. 1. Schematic representation of key physio- pathological events and potential targets for disease modulated by leptin at bone and
cartilage level.
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cular permeability in inﬂamed joints), suggests that leptin
may trigger cartilage destruction, particularly when associ-
ated with some local factors. Actually, the adipokine syner-
gizes with IL1, whose expression is markedly inﬂuenced by
leptin itself in chondrocytes as assessed by the authors of
this article, to increase nitric oxide production. As men-
tioned above, nitric oxide is known to interfere with chon-
drocyte function resulting in the loss of cartilage matrix,
inhibition of type II collagen synthesis, and activation of
metalloproteinases. Regarding this last issue, Tsezou
et al.19 reported a leptin dose-dependent increase of
MMP9 and MMP13, two of the major cartilage matrix de-
grading metalloproteases that mediate the destructive pro-
cess in OA.
To note, a similar induction is exerted also by another rel-
evant adipokine, adiponectin, in synovial ﬁbroblast from pa-
tients with OA20, suggesting in this way that the adipokine
network can be clearly associated with key pathways of
matrix degradation and may signiﬁcantly contribute to the
initiation and/or progression of OA.
In conclusion, we can consider now that OA is a metabolic
disease in which all the components of the joint, including
bone, muscles, synovia and cartilage are generally affected
by adipokine dysregulation or hyperactivity. The leptin ef-
fects discussed above may participate in the pathogenesis
of OA, together with mechanical overload (due to the activa-
tion of mechanoreceptors at the chondrocyte surface),
as well as other speciﬁc conditions such as obesity and
its associated complications (vascular inﬂammation, type
2 diabetes, and severe alteration of lipids and glucose me-
tabolism). However, in light of the recent published litera-
ture, it is now evident that leptin can be easily considered
as a prototypical pro-inﬂammatory adipokine linking obesity,
inﬂammation and immunity and the data from Simopoulou
et al.19 provide this last piece of the puzzle increasing our
understanding of the mechanisms by which obesity leads
to chronic inﬂammation. These data also might have impor-
tant implications for novel therapeutic strategies to reduce
the morbidity of OA particularly in obese subjects. However,
to stick to realities, the current understanding of the actions
of leptin and other newly recognized adipokines is still too
incomplete to generate well-supported therapeutic hypothe-
ses. The rate at which their roles are being clariﬁed none-
theless makes it certain that they, too, will soon be central
to pharmacotherapeutic approaches to obesity-induced dis-
eases including OA.
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